DE-RISKED AND READY TO MOVE: THIS ONE’S ALREADY VETTED AND APPROVED!
If you’re not identifying de-risked companies, you’re not really investing. That’s just flat-out gambling and I don’t support it. No company passes my screening process unless it has a clear and present catalyst – and in the case of companies that develop novel solutions, there needs to be positive precedents from governmental regulators.
In other words, there’s no point in fighting against the government as an investor. You saw what happened to cannabis stocks after word got out that Canadian regulators were ready to approve it for public use. Investors who took positions ahead of everyone else were the ones who saw the biggest and fastest profits.
That’s how you avoid the home-run-or-strikeout gambler mindset. The strategy is to get behind a risk-reduced, value-added company like Champignon Brands (CSE:SHRM, OTC:SHRMF). The company has two clinics to research, develop and deliver medical treatments for mood disorders including depression, post-traumatic stress disorder (PTSD), anxiety, and more.
With a projected global market for mental health/neurological disorders of $128.9 billion by the year 2025, this is not a speculative market. Yale University, Johns Hopkins, and the Universities of Miami and Wisconsin are all researching the potential of psychedelic medical applications for improved mental health.
Among the most promising medical treatments for these mood disorders are ketamine, psilocybin, and MDMA. Champignon is accelerating its current research with plans to move efficiently through clinical trials with the objective of developing next-generation medicinal psychedelics.
Champignon is preparing to bring therapies to market featuring safe doses of ketamine, psilocybin, and MDMA. The company also fully owns three other segments to complete the chain and potentially deliver life-enhancing therapies to the eager public.
Having in-house clinics and basically controlling the product chain may prove to be a major time and money saver for Champignon Brands. The cost savings, along with the serious first-mover advantage, is an unbeatable combination that’s already revolutionizing the market.
Keep in mind that ketamine, psilocybin, and MDMA have all been fast-tracked by the U.S. Food and Drug Administration research and development pertaining to mood disorders. In other words, the stamp of approval is already there for the research, opening up the possibility of product availability in the near future.
Champignon’s unique solutions are poised to transform the medical community while the company attempts to secure its share of the $10 billion North American market for pharmacologic depressive disorder treatments.
And that’s what a truly de-risked investment looks like: government clearance, a built-in consumer base, and an early-stage market with one company clearly ahead of the pack.
RECOMMENDATION: MAKE CHAMPIGNON BRANDS (CSE: SHRM, OTC: SHRMF) A CORE STOCK IN YOUR PORTFOLIO.
Consider becoming a shareholder of Champignon Brands (CSE: SHRM, OTC: SHRMF))
For further updates on Champignon Brands, subscribe now!